Genentech's Tecentriq Receives FDA Approval a Combination Therapy- for mNon-Sq NSCLC with No EGFR or ALK Genomic Tumor Aberrations
Shots:
- The approval is based on P-III IMpower150 study results assessing Tecentriq + CT (paclitaxel & carboplatin) + Avastin (bevacizumab) (w or w/o) in 1202 patients in ratio (1:1:1) with Stage IV or recurrent mNon-sq NSCLC not treated with CT
- P-III IMpower150 study results (Tecentriq + carboplatin and paclitaxel- Tecentriq +Avastin + carboplatin & paclitaxel- Avastin + carboplatin & paclitaxel): OS (19.2 vs 14.7 mos.); reduced risk of disease worsening or death 29%- ORR (55% vs 42%); CR 4%; PR 51%; mDOR (10.8 vs 6.5 mos.)
- Tecentriq is a mAb used for binding PD-L1 protein- while blocking interaction with PD-1 and B7.1 receptors
Ref: Genentech | Image: Nature
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com